Flagship Pioneering has launched a new research program with Pfizer through its portfolio company Repertoire Immune Medicines, focused on the development of T cell receptor (TCR) bispecifics for metastatic prostate cancer. This marks the eighth initiative under the broader Flagship–Pfizer strategic alliance. The program will harness Repertoire’s DECODE platform to map immune synapse interactions and […]
Novartis gains FDA orphan status for iptacopan in myasthenia gravis. Explore how this oral complement inhibitor could challenge biologics in neurology.
FDA approves subcutaneous Lunsumio VELO for relapsed follicular lymphoma. Explore what this changes for bispecific antibodies and outpatient cancer care.
Mercury Bio Inc., a biotechnology company focused on large-molecule therapeutics, has announced a strategic collaboration with Meta-Flux, a disease simulation company that leverages artificial intelligence, to advance drug discovery programs for Parkinson’s disease and Alzheimer’s disease. The partnership combines Mercury Bio’s proprietary yeast extracellular vesicle (yEV) delivery technology with Meta-Flux’s disease-scale computational modeling platform, with […]
Tolmar Inc. has received expanded approval from the U.S. Food and Drug Administration for Rubraca (rucaparib), enabling its use before chemotherapy in patients with metastatic castration-resistant prostate cancer who carry BRCA mutations. The decision was based on results from the TRITON3 Phase 3 trial, which showed Rubraca to be the first and only PARP inhibitor […]
